Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 14/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.58 |
| ▸ | TUBB | P07437 | 3/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.58 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.58 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4321863 | 0.93 | TUBB4A (0.68) | MYBNPC1SMN1; SMN2TUBB4ATUBB | |
| SCHEMBL4320224 | 0.93 | MYB (0.60) | MYBNPC1SMN1; SMN2TUBB4ATUBB | |
| SCHEMBL4343035 | 0.88 | MYB (0.53) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4339420 | 0.88 | TUBB4A (0.56) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4335976 | 0.87 | MYB (0.63) | MYBNPC1SMN1; SMN2TUBB4ATUBB | |
| SCHEMBL4328201 | 0.86 | TUBB4A (0.57) | MYBNPC1SMN1; SMN2TUBB4ATUBB | |
| SCHEMBL5618119 | 0.86 | HSD17B10 (0.64) | MYBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4321663 | 0.84 | MAPK1 (0.54) | MYBSMN1; SMN2RAB9A | |
| SCHEMBL4332182 | 0.83 | MYB (0.46) | MYBRAB9A | |
| SCHEMBL4320003 | 0.83 | MYB (0.51) | MYBNPC1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | claimed |
| US-7528164-B2 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7235674-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-7015328-B2 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-04-28 | — | — | US | disclosed |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060104998-A1 | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP2 | MYB 326/4885NPC1 3948/4885SMN1; SMN2 4242/4885 |
| US-20030114485-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP1, CASP5 | MYB 1001/4885NPC1 739/4885SMN1; SMN2 4828/4885 |
| US-20050090526-A1 | Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP7, CASP5, CASP14 | MYB 959/4885NPC1 916/4885SMN1; SMN2 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.